The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.